99 related articles for article (PubMed ID: 12534084)
1. [Questionable group concept. How interchangeable are so-called analog drug preparations?].
Wehling M
MMW Fortschr Med; 2002 Nov; 144(46):56-8. PubMed ID: 12534084
[TBL] [Abstract][Full Text] [Related]
2. Use and cost of branded and generic drugs in patients with coronary heart disease--results from a prospective survey of 1008 patients in two London hospitals.
Corp EV; Antoniou S; Wright PG; Khachi H; Vercaeren S; Wald DS
QJM; 2009 Dec; 102(12):843-9. PubMed ID: 19828644
[TBL] [Abstract][Full Text] [Related]
3. Optimal medical management of peripheral arterial disease.
Rice TW; Lumsden AB
Vasc Endovascular Surg; 2006; 40(4):312-27. PubMed ID: 16959725
[TBL] [Abstract][Full Text] [Related]
4. [Added organ protection at little cost. Double savings with ACE inhibitors].
MMW Fortschr Med; 2003 Nov; 145(48):63. PubMed ID: 14725008
[No Abstract] [Full Text] [Related]
5. The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease.
Ezekowitz J; McAlister FA; Humphries KH; Norris CM; Tonelli M; Ghali WA; Knudtson ML;
J Am Coll Cardiol; 2004 Oct; 44(8):1587-92. PubMed ID: 15489090
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
7. Pravastatin and coronary heart disease.
Bloom JM
N Engl J Med; 1999 Apr; 340(14):1116-7. PubMed ID: 10206831
[No Abstract] [Full Text] [Related]
8. Should patients receive secondary prevention medications for free after a myocardial infarction? An economic analysis.
Choudhry NK; Avorn J; Antman EM; Schneeweiss S; Shrank WH
Health Aff (Millwood); 2007; 26(1):186-94. PubMed ID: 17211028
[TBL] [Abstract][Full Text] [Related]
9. Economic analysis of treatments reducing coronary heart disease mortality in England and Wales, 2000-2010.
Fidan D; Unal B; Critchley J; Capewell S
QJM; 2007 May; 100(5):277-89. PubMed ID: 17449875
[TBL] [Abstract][Full Text] [Related]
10. Potential novel pharmacological therapies for myocardial remodelling.
Landmesser U; Wollert KC; Drexler H
Cardiovasc Res; 2009 Feb; 81(3):519-27. PubMed ID: 19019834
[TBL] [Abstract][Full Text] [Related]
11. On equivalence.
Malik P
Can J Cardiol; 2003 Aug; 19(9):992. PubMed ID: 12915924
[No Abstract] [Full Text] [Related]
12. [Decreasing LDL level moderately or drastically. Is differential therapy with statins available? (interview by Dirk Einecke)].
März W
MMW Fortschr Med; 2004 Jul; 146(27-28):53. PubMed ID: 15526673
[No Abstract] [Full Text] [Related]
13. Adherence to statins, beta-blockers and angiotensin-converting enzyme inhibitors following a first cardiovascular event: a retrospective cohort study.
Blackburn DF; Dobson RT; Blackburn JL; Wilson TW; Stang MR; Semchuk WM
Can J Cardiol; 2005 May; 21(6):485-8. PubMed ID: 15917876
[TBL] [Abstract][Full Text] [Related]
14. AT1 receptor blockade for the prevention of cardiovascular events after myocardial infarction.
Azadpour M; Lamas GA
Expert Rev Cardiovasc Ther; 2004 Nov; 2(6):891-902. PubMed ID: 15500434
[TBL] [Abstract][Full Text] [Related]
15. Treatment and secondary prevention of ischemic coronary events in Croatia (TASPIC-CRO study).
Reiner Z; Mihatov S; Milicić D; Bergovec M; Planinc D;
Eur J Cardiovasc Prev Rehabil; 2006 Aug; 13(4):646-54. PubMed ID: 16874158
[TBL] [Abstract][Full Text] [Related]
16. Economic implications of treatment guidelines for congestive heart failure.
Shibata MC; Nilsson C; Hervas-Malo M; Jacobs P; Tsuyuki RT
Can J Cardiol; 2005 Dec; 21(14):1301-6. PubMed ID: 16341301
[TBL] [Abstract][Full Text] [Related]
17. [Therapy relevant differences in beta blockers and ACE inhibitors. Innovation or plagiarism?].
Dominiak P; Dendorfer A; Raasch W
MMW Fortschr Med; 2002 Jan; 144(1-2):50-4. PubMed ID: 11847884
[TBL] [Abstract][Full Text] [Related]
18. beta-Blocker therapy in heart failure.
Doughty RN
Heart Fail Monit; 2000; 1(1):2-7. PubMed ID: 12634875
[TBL] [Abstract][Full Text] [Related]
19. C-reactive protein (CRP)-lowering agents.
Prasad K
Cardiovasc Drug Rev; 2006; 24(1):33-50. PubMed ID: 16939632
[TBL] [Abstract][Full Text] [Related]
20. An approach to heart failure and diabetes mellitus.
Fonarow GC
Am J Cardiol; 2005 Aug; 96(4A):47E-52E. PubMed ID: 16098844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
